Home・Listă Acțiuni・Ovid therapeutics Inc

Ovid therapeutics Inc

Închisă

SectorSănătate

2.91 3.56

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.65

Maxim

2.84

Indicatori cheie
By Trading Economics
Venit	2M -15M
Vânzări	733K 733K
EPS	-0.08
Marjă de profit	-2,047.476
Angajați	23
EBITDA	566K -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+121.63% upside

Dividende
By Acuity
Următoarele câștiguri	11 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	50M 539M
Deschiderea anterioară	-0.65
Închiderea anterioară	2.91

Sentimentul știrilor

By Acuity

50%

150 / 340 Clasament în Healthcare

Ovid therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 aug. 2026, 19:16 UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

21 aug. 2026, 19:46 UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

20 aug. 2026, 23:31 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

19 aug. 2026, 21:21 UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

14 aug. 2026, 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13 aug. 2026, 19:16 UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12 aug. 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7 aug. 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6 aug. 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5 aug. 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4 aug. 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3 aug. 2026, 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31 iul. 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27 iul. 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22 iul. 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20 iul. 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Comparație

Modificare preț

Ovid therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

121.63% sus

Prognoză pe 12 luni

Medie 6.25 USD 121.63%

Maxim 9 USD

Minim 4 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOvid therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Ovid therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

150 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.